161 related articles for article (PubMed ID: 38206369)
1. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
Gao S; Dong F; Yang P; Chen Y; Wang Y; Wang J; Shi Y; Jing H
Ann Hematol; 2024 Jun; 103(6):1979-1987. PubMed ID: 38206369
[TBL] [Abstract][Full Text] [Related]
2. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study.
Gao S; Li Q; Dong F; Yang P; Chen Y; Wang J; Wang Y; Jing H
Leuk Res; 2022 Apr; 115():106793. PubMed ID: 35248783
[TBL] [Abstract][Full Text] [Related]
4. Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China.
Gao W; Jian Y; Du J; Li X; Zhou H; Zhang Z; Yang G; Wang G; Tian Y; Li Y; Wu Y; Fu W; Li J; Chen W
Cancer Med; 2020 Nov; 9(21):7819-7829. PubMed ID: 32881351
[TBL] [Abstract][Full Text] [Related]
5. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
[TBL] [Abstract][Full Text] [Related]
6. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
Tao Y; Jin SW; Wang Y; Tang SJ; Liu YF; Xu J; Pan MM; Zhang WP; Mi JQ
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):48-54. PubMed ID: 36987723
[No Abstract] [Full Text] [Related]
7. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
8. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
[TBL] [Abstract][Full Text] [Related]
9. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
[TBL] [Abstract][Full Text] [Related]
10. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
Wang J; Zhang LN; Shi QL; Qu XY; Chen LJ; Li JY; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):822-828. PubMed ID: 33190439
[No Abstract] [Full Text] [Related]
11. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
Deng P; Zhou YL; Wei YL; Li P; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
Nahi H; Våtsveen TK; Lund J; Heeg BM; Preiss B; Alici E; Møller MB; Wader KF; Møller HE; Grøseth LA; Østergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
Eur J Haematol; 2016 Jan; 96(1):46-54. PubMed ID: 25779478
[TBL] [Abstract][Full Text] [Related]
13. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic and survival analysis in 315 multiple myeloma patients; five with orbital and eight with extramedullary disease.
Tucker SM; Zaihra T
Orbit; 2023 Dec; 42(6):603-611. PubMed ID: 36697375
[TBL] [Abstract][Full Text] [Related]
15. Identification of patients at high risk of secondary extramedullary multiple myeloma development.
Stork M; Sevcikova S; Minarik J; Krhovska P; Radocha J; Pospisilova L; Brozova L; Jarkovsky J; Spicka I; Straub J; Pavlicek P; Jungova A; Jelinek T; Sandecka V; Maisnar V; Hajek R; Pour L
Br J Haematol; 2022 Feb; 196(4):954-962. PubMed ID: 34726261
[TBL] [Abstract][Full Text] [Related]
16. Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study.
Chen H; Zhou N; Shi H; Yu W; Wu L; Zhou F
Hematology; 2023 Dec; 28(1):2177979. PubMed ID: 36794720
[TBL] [Abstract][Full Text] [Related]
17. The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients.
You H; Jin S; Wu C; Wang Q; Yan S; Yao W; Shi X; Shang J; Yan L; Yao Y; Wang J; Wang P; Pan J; Wu D; Fu C
Front Oncol; 2022; 12():938392. PubMed ID: 36276097
[TBL] [Abstract][Full Text] [Related]
18. Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease.
Wang J; Shen N; Shen X; Zhang R; Jin Y; Li J; Chen L
Ann Med; 2023; 55(2):2281657. PubMed ID: 38086395
[No Abstract] [Full Text] [Related]
19. [Clinical Analysis of 46 Cases of Multiple Myeloma with Extramedullary Disease].
Chao Y; Fan L; Gao XY; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):115-121. PubMed ID: 33554807
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]